off brand glp 1 FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs Compounded GLP-1 ban: What providers

Understanding the leptin induced suppression of GLP1 inputs to the hypothalamus during weight gain and/or in the obese state may provide an additional pathology of obesity and diabetes

Lixisenatide and exenatide are much weaker GLP-1 drugs compared with semaglutide, tirzepatide and several others that are in clinical trials as shown below for weight loss

New Insights into the Use of LiraglutideImpact on Cardiovascular Risk and Microvascular Outcomes

The clinical resources mentioned during the podcast are part of a subscription to Pharmacists Letter, Pharmacy Technicians Letter , and Prescriber Insights : Chart: GLP-1 and GIP/GLP-1 Receptor Agonist Interactive Comparison Chart Chart: Treatment and Prevention of Hair Loss FAQ: Managing Erectile Dysfunction Chart: Perioperative Management of Diabetes Article: Keep Potential Eye Risks With GLP-1 Agonists in Sight Suicide & Crisis Lifeline Call or Text: 988 Email us: [email protected] The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment

This degree of weight loss can shift patients from severe to mild OSA, or from mild OSA to below the diagnostic threshold entirely